Efficacy News and Research

RSS

Enzo Life Sciences introduces ELISA system to detect SMN protein

Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.

16 Mar 2011

Argon acquires global rights to market, distribute Rex Medical's Option Retrievable Inferior Vena Cava Filter

Argon Medical Devices, Inc. announced today that it has entered into a definitive license agreement with Rex Medical, LP ("Rex Medical") for exclusive global rights to market and distribute the Option™ Retrievable Inferior Vena Cava Filter, an implantable device used in the prevention of Pulmonary Embolism (PE).

15 Mar 2011

XTIO2 presents XTI 360 ANTI-GERM SYSTEM to 83rd Academy Award-nominees

XTIO2 INC. (XTI) presented the 83rd Academy® Award-nominees with the XTI ANTI-GERM / ANTI-VOC / ANTI-ALLERGY SYSTEM, consisting of XTI 360™ Nanocoating and XTI™ Nano-Facemask. It is the world's most effective preventive measure and the best defense against germs transmitted via air and contact surfaces.

15 Mar 2011

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

An inexpensive type 2 diabetes drug that has been around for more than 15 years works just as well and has fewer side effects than a half-dozen other, mostly newer and more expensive classes of medication used to control the chronic disease, new Johns Hopkins research suggests.

15 Mar 2011

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Oxford BioMedica plc, a leading gene therapy company, today announces that further analyses of the TroVax Renal Immunotherapy Survival Trial, a randomised, double-blind, placebo-controlled Phase III study, have been accepted for publication in Cancer Immunology, Immunotherapy, the official journal of the Association for Cancer Immunotherapy.

15 Mar 2011

Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS

Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein therapies to treat cardiovascular and metabolic diseases, today announced the start of the Phase 2 CHI-SQUARE study of CER-001 in patients with acute coronary syndrome.

15 Mar 2011

ExonHit receives CE mark approval for AclarusDx to diagnose AD

ExonHit Therapeutics announces today CE marking of AclarusDx, its blood-based test intended to help in the diagnosis of Alzheimer's disease. This gives AclarusDx the status of In Vitro Diagnostic.

15 Mar 2011

Covidien to present new data on hernia, abdominal wall repair products at San Francisco

Covidien, a leading global provider of healthcare products, announced that new data on its hernia and abdominal wall repair products will be presented at Hernia Repair 2011, the 14th Annual Meeting & Scientific Program of the American Hernia Society.

15 Mar 2011

New study: Two peptide agent combination might block tumor growth

A new study suggests that combining two experimental anticancer peptide agents might simultaneously block formation of new tumor blood vessels while also inhibiting the growth of tumor cells.

15 Mar 2011

Positive top-line results from IPX066 Phase III study in patients with PD

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced statistically significant, positive, top-line results of the ADVANCE-Parkinson's Disease Phase III clinical study of the safety and efficacy of IPX066 versus immediate-release carbidopa-levodopa in advanced PD patients experiencing motor fluctuations.

15 Mar 2011

Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas

Repligen Corporation reported today positive top-line results from a Phase 3 study to evaluate the safety and efficacy of RG1068, synthetic human secretin, to improve magnetic resonance imaging (MRI) of the pancreas in patients with pancreatic disease using endoscopy (ERCP) as a diagnostic reference.

14 Mar 2011

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Euthymics Bioscience, Inc. today announced the initiation of an advanced clinical study of its lead product candidate EB-1010 for the treatment of major depressive disorder (MDD). The TRIADE (Triple Reuptake Inhibitor Anti-Depressant Effects) trial is a phase 2b/3a clinical trial designed to assess the safety and efficacy of EB-1010, a novel serotonin-preferring triple reuptake inhibitor.

14 Mar 2011

Biodel selects BIOD-105, BIOD-107 recombinant human insulin formulations for clinical testing, development

Biodel Inc. announced today that it has selected two new formulations of recombinant human insulin for clinical testing and is accelerating clinical development plans of these mealtime insulin drug candidates. The new formulations, BIOD-105 and BIOD-107, are designed to result in more rapid insulin action compared to currently marketed meal time insulin analogs while maintaining an injection site tolerability profile comparable to currently marketed insulins.

14 Mar 2011

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 2 study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent and serious complication of end-stage renal disease (ESRD).

14 Mar 2011

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that the first patient has been dosed in its pivotal Phase III EVOLVE (EpanoVa fOr Lowering Very high triglyceridEs) trial for Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega-3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

14 Mar 2011

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Anacor Pharmaceuticals announced today that it has completed enrollment in its Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that affects approximately 7.5 million people in the United States and over 100 million people worldwide.

14 Mar 2011

Nanotechnology might provide greater efficacy of medicines for brain disease

Technology has been developed within Top Institute Pharma that helps medicines be absorbed quicker into the blood and thus be more effective. Researcher Hans de Waard, who is associated with the University of Groningen, will obtain his doctorate on this subject on March 11. De Waard: "Many current medicines are not easily dissolved in the digestive tract, which means that they barely reach the bloodstream.

14 Mar 2011

Combination therapy may overcome Herceptin-resistant breast cancer

Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine.

14 Mar 2011

Alzheimer's vaccine - First evidence for efficacy

AFFiRiS' Alzheimer's vaccine candidate AD02 showed indicative evidence for potential efficacy in a phase I clinical trial. This was demonstrated by the analysis of the data from secondary clinical study endpoints.

12 Mar 2011

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.

11 Mar 2011

Efficacy News and Research

Enzo Life Sciences introduces ELISA system to detect SMN protein

Argon acquires global rights to market, distribute Rex Medical's Option Retrievable Inferior Vena Cava Filter

XTIO2 presents XTI 360 ANTI-GERM SYSTEM to 83rd Academy Award-nominees

Type 2 diabetes drug less likely to cause weight gain, raise cholesterol levels

Oxford Biomedica’s TroVax(R) TRIST Phase III study results to be published in Cancer Immunology, Immunotherapy

Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS

ExonHit receives CE mark approval for AclarusDx to diagnose AD

Covidien to present new data on hernia, abdominal wall repair products at San Francisco

New study: Two peptide agent combination might block tumor growth

Positive top-line results from IPX066 Phase III study in patients with PD

Repligen reports positive results from RG1068 Phase 3 study to improve MRI of the pancreas

Euthymics Bioscience initiates EB-1010 phase 2b/3a TRIADE clinical trial for major depressive disorder

Biodel selects BIOD-105, BIOD-107 recombinant human insulin formulations for clinical testing, development

KAI initiates enrollment in KAI-4169 Phase 2 study for secondary hyperparathyroidism

Omthera commences dosing in pivotal Epanova Phase III EVOLVE trial in patients with very high triglycerides

Anacor completes enrollment in AN2728 Phase 2b trial in psoriasis

Nanotechnology might provide greater efficacy of medicines for brain disease

Combination therapy may overcome Herceptin-resistant breast cancer

Alzheimer's vaccine - First evidence for efficacy

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News